Compare EXR & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXR | ALNY |
|---|---|---|
| Founded | 1977 | 2002 |
| Country | United States | United States |
| Employees | N/A | 115 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.3B | 34.2B |
| IPO Year | 2004 | 2004 |
| Metric | EXR | ALNY |
|---|---|---|
| Price | $132.23 | $254.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 28 |
| Target Price | $144.80 | ★ $471.00 |
| AVG Volume (30 Days) | 1.2M | ★ 1.3M |
| Earning Date | 04-28-2026 | 04-30-2026 |
| Dividend Yield | ★ 4.61% | N/A |
| EPS Growth | 13.90 | ★ 206.88 |
| EPS | 2.39 | ★ 2.71 |
| Revenue | ★ $3,377,542,000.00 | $1,037,418,000.00 |
| Revenue This Year | N/A | $52.67 |
| Revenue Next Year | $3.63 | $31.48 |
| P/E Ratio | ★ $55.10 | $94.23 |
| Revenue Growth | 3.70 | ★ 22.88 |
| 52 Week Low | $125.71 | $197.81 |
| 52 Week High | $158.88 | $495.55 |
| Indicator | EXR | ALNY |
|---|---|---|
| Relative Strength Index (RSI) | 33.05 | 53.41 |
| Support Level | $128.34 | $236.00 |
| Resistance Level | $151.04 | $272.08 |
| Average True Range (ATR) | 2.46 | 8.32 |
| MACD | -0.30 | 0.83 |
| Stochastic Oscillator | 16.13 | 79.31 |
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages more than 4,200 self-storage properties in 43 states, with over 330 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.